Fennec Pharmaceuticals Inc.
PEDMARK
reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors
Resolved
1376days ago
Approval decision · ~ Sep 30, 2022 estimated
What's at stake
A final FDA approval decision on PEDMARK for reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors is expected ~ Sep 30, 2022.
Primary source
· SEC 8-K
verified 15h ago
“The Company is pursuing registration in Japan and is also exploring partnering or licensing opportunities for PEDMARK.”